Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis ® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee ® ...
After taking most of a decade to approve its first interchangeable biosimilar (Semglee (insulin glargine-yfgn), the U.S. Food and Drug Administration has approved three interchangeable biosimilars ...
The Food and Drug Administration has approved the first interchangeable biosimilar product, Mylan’s Semglee (insulin glargine-yfgn). Semglee is both biosimilar to and interchangeable with Lantus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback